Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe

Torrent board approves Scheme of Amalgamation of Curatio Health Care

The scheme is subject to statutory and regulatory approvals as may be necessary.

BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer

He has published more than 100 research papers in several prestigious national and international journals

Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules

According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

Cadila Pharmaceuticals appoints Ashraf Allam as Global COO

Allam was serving recently as the CEO at Public Investment Fund

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Enhertu to demonstrate a significant survival benefit vs. chemotherapy

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet

The product is backed by required scientific proof and comparative bioequivalence studies